Radioiodination of Pimonidazole as a Novel Theranostic Hypoxia Probe

Basit Öğe Kaydı
dc.authoridKOZGUS GULDU, OZGE/0000-0001-7028-0720
dc.authoridKILCAR, AYFER YURT/0000-0003-0866-7515
dc.authoridKARATAY, Kadriye Busra/0000-0002-2811-4689
dc.authorwosidKOZGUS GULDU, OZGE/GLQ-8246-2022
dc.authorwosidKILCAR, AYFER YURT/Q-3053-2019
dc.authorwosidtekin, volkan/AEE-4731-2022
dc.authorwosidMedine, Emin İlker/GLS-0483-2022
dc.contributor.authorInci, Ilknur Demir
dc.contributor.authorTekin, Volkan
dc.contributor.authorKilcar, Ayfer Yurt
dc.contributor.authorGuldu, Ozge Kozgus
dc.contributor.authorMedine, Emin Ilker
dc.contributor.authorKaratay, Kadriye Busra
dc.contributor.authorDervis, Emine
dc.date.accessioned2023-01-12T20:11:44Z
dc.date.available2023-01-12T20:11:44Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground: Tumors are defined as abnormal tissue masses, and one of the most important factors leading to the growth of these abnormal tissue masses is Vascular Endothelial Growth Factor, which stimulates angiogenesis by releasing cells under hypoxic conditions. Hypoxia has a vital role in cancer therapy, thus it is important to monitor hypoxia. The hypoxia marker Pimonidazole (PIM) is a candidate biomarker of cancer aggressiveness. Objective: The study aimed to perform radioiodination of PIM with Iodine-131 (I-131) to join a theranostic approach. For this purpose, PIM was derived as PIM-TOS to be able to be radioiodinated. Methods: PIM was derived via a tosylation reaction. Derivatization product (PIM-TOS) was radioiodinated by using iodogen method and was analyzed by High-Performance Liquid Chromatography and Liquid chromatography-mass spectrometry. Thin layer radiochromatography was utilized for its quality control studies. Results: PIM was derived successfully after the tosylation reaction. The radioiodination yield of PIM-TOS was over 85%. Conclusion: In the current study, radioiodination potential of PIM with I-13(1), as a potential theranostic hypoxia agent was investigated. Further experimental studies should be performed for developing a novel hypoxia probe including theranostics approaches.en_US
dc.description.sponsorshipEge University Scientific Research Projects Coordination Unit., Izmir, Turkey [2012NBE016]en_US
dc.description.sponsorshipThis study was financially supported by the Ege University Scientific Research Projects Coordination Unit., Izmir, Turkey (Grant Number: 2012NBE016).en_US
dc.identifier.doi10.2174/1874471013666200331114908
dc.identifier.endpage50en_US
dc.identifier.issn1874-4710
dc.identifier.issn1874-4729
dc.identifier.issue1en_US
dc.identifier.pmid32228432en_US
dc.identifier.startpage46en_US
dc.identifier.urihttps://doi.org/10.2174/1874471013666200331114908
dc.identifier.urihttps://hdl.handle.net/11454/78180
dc.identifier.volume14en_US
dc.identifier.wosWOS:000641557600007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPimonidazoleen_US
dc.subjecttosylationen_US
dc.subjectradioiodinationen_US
dc.subjectiodine-131en_US
dc.subjecttheranosticen_US
dc.subjecthypoxiaen_US
dc.titleRadioiodination of Pimonidazole as a Novel Theranostic Hypoxia Probeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu